FINWIRES · TerminalLIVE
FINWIRES

BioAge Labs Says Drug Candidate Shows 'Best-in-Class Reductions' in Inflammatory Biomarkers in Phase 1 Trial With Obese Patients

By

BioAge Labs (BIOA) said Tuesday its experimental BGE-102 drug demonstrated "best-in-class reductions" in inflammatory biomarkers during a phase 1 trial involving participants with obesity.

Both the 60 mg and 120 mg daily doses lowered high-sensitivity C-reactive protein levels by at least 85% while maintaining a favorable safety profile, the company said.

The company plans to begin a phase 2 study focused on cardiovascular risk during H1, with initial data expected by the end of the year.

BioAge also intends to launch a separate proof-of-concept trial for diabetic macular edema in mid-2026 to evaluate the treatment's effect on retinal diseases.

Shares of the company rose 9% in Tuesday's premarket activity.

Price: $20.49, Change: $+1.69, Percent Change: +8.99%

Related Articles

Wire

IDP Education to Introduce Malaysia as Study Destination

IDP Education (ASX:IEL) expanded its range of study destinations by supporting students to study in Malaysia, according to a Tuesday statement.The company cited changing student preferences as a reason for the move, with growing demand for new destinations offering strong education quality, career outcomes, and affordable study options.The initial rollout will focus on a select number of markets as part of a phased pilot.IDP Education's shares declined 1% in recent trading on Tuesday.

ASX:IEL
Wire

Infratil Says Moody's Assigns CDC Data Centers 'Baa2' Rating, Stable Outlook

Infratil (NZE:IFT, ASX:IFT) said Moody's Ratings has assigned CDC Data Centers Australia its first public investment grade credit rating of "Baa2" with a stable outlook, according to Tuesday filings with the Australian and New Zealand bourses.The rating reflects CDC's strong financial position, stable long-term contracted revenues, and exceptionally long lease durations averaging 28.4 years, per the filing.The rating will enable CDC to improve access to capital markets, supporting further large-scale infrastructure development driven by rising demand from government, hyperscale cloud providers, and critical industries, the filing added.The company's Kiwi shares shed 1% in recent Tuesday trade.

ASX:IFTNZE:IFT
Wire

Spruce Biosciences Begins Public Offering of Stock, Prefunded Warrants; Shares Fall After Hours

Spruce Biosciences (SPRB) said late Monday it commenced an underwritten public offering of common shares or related prefunded warrants.The company expects to grant underwriters a 30-day option to buy up to 15% more stock at the public offering price, less underwriting discounts and commissions.The offering is subject to market and other conditions, Spruce said.Spruce shares fell 13% in after-hours trading.

$SPRB